Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Beleave Inc    BE   CA0775611084

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Beleave Inc.: No Material Change

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2017 | 08:11pm CET

Beleave Inc. (CNSX: BE) at the request of the Investment Industry Regulatory Organization of Canada wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Consistent with the Company’s press release dated September 26, 2016, the Company continues work with Health Canada towards the scheduling of a pre-licensing inspection of its proposed facility.

About Beleave Inc.

Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“ FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.

Forward-Looking Statements

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the ACMPR licensing process and meeting the requirements of the ACMPR. No assurances are given as to the anticipated timing of delivering the confirmations to Health Canada described in this press release nor the anticipated timing of any pre-licensing inspection. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Connect with Beleave Inc. (CNSX:BE) to receive an Investor Presentation.

The post Beleave Inc.: No Material Change appeared first on Investing News Network.

© 2017 Investing News Network. All Rights Reserved., source Investing News Network

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BELEAVE INC
12/08 BELEAVE : Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes
12/06 BELEAVE : Closes $9.95 Million Non-Brokered Private Placement of Units
12/01 BELEAVE : Announces Upsize of Previously Announced Non-Brokered Private Placemen..
11/30 BELEAVE : Aims to Raise Awareness by Supporting Don't Drive High Campaign
10/25 BELEAVE : and Dr. Michael Rogers Begin Research in Cannabis Food and Drug Delive..
10/17 CANNABIS WHEATON INCOME : REPEAT - Cannabis Wheaton Provides Initial Advance of ..
10/17 CANNABIS WHEATON INCOME : Provides Initial Advance of $5,000,000 to Beleave
10/11 BELEAVE : Appoints New Chief Executive Officer Andrew Wnek
10/05 CANNABIS WHEATON INCOME : REPEAT - Cannabis Wheaton and Beleave Sign Definitive ..
10/05 CANNABIS WHEATON INCOME : and Beleave Sign Definitive Agreement for up to $10,00..
More news
Financials ( CAD)
Sales 2017 -
EBIT 2017 -4,80 M
Net income 2017 -4,80 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 -
Capitalization -
Duration : Period :
Beleave Inc Technical Analysis Chart | BE | CA0775611084 | 4-Traders
Mean consensus BUY
Number of Analysts 1
Average target price 1,80  
Spread / Average Target
EPS Revisions
Andrew T. Wnek Chief Executive Officer & Independent Director
Roger Ferreira Director & Chief Science Officer
Vasilios Panagiotakopoulos Chief Operational Officer & Director
Bojan Krasic Chief Financial Officer & Director
Gordon Richard Harvey Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB0.85%11 452
BLUEBIRD BIO INC177.39%9 249